IONS Ionis Pharmaceuticals Inc.

54.27
+0.53  (1%)
Previous Close 53.74
Open 54.03
Price To book 21.97
Market Cap 6772652002
Shares 124,795,504
Volume 203,557
Short Ratio 6.64
Av. Daily Volume 1,408,342

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171184136
  2. 8-K - Current report 171181102
  3. 8-K - Current report 171170641
  4. CT ORDER - Confidential treatment order 171150254
  5. 8-K - Current report 171049664

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 completion of enrollment noted June 22, 2017. Top-line data due around the end of 2017.
IONIS-HTT Rx
Huntington's Disease
Phase 1/2 interim data released November 2016.
IONIS-ANGPTL3-LRx
Cardiovascular disease
Phase 3 data released May 15, 2017 - primary endpoint met but with safety concerns. Data presented November 2, 2017. NDA submission announced November 6, 2017.
Inotersen (IONIS-TTRRx)
NEURO-TTR - familial amyloid polyneuropathy (FAP).
Approved December 23, 2016.
SPINRAZA - Nusinersen
Spinal muscular atrophy (SMA)
Phase 2 data released November 2016.
IONIS-FXIRx
End-stage renal disease
Phase 2 data released 3Q 2015
IONIS-APO(a)Rx
High lipoprotein(a), or Lp(a)
Phase 2 data released January 4, 2016.
IONIS-GCGRRx
Type 2 diabetes
Phase 2 released Feb 2015. Achieved statistically significant results but data released was as of 36 weeks rather than 27 weeks for the primary endpoint
IONIS-PTP1BRx
Type 2 diabetes
Partner GSK announced May 2016 decision not to be proceed with Phase 3 outcome trial
Inotersen (IONIS-TTRRx)
CARDIO-TTR - Cardiomyopathy form of TTR amyloidosis.

Latest News

  1. See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
  2. Ionis Pharmaceuticals Licenses Second Orally Delivered Antisense Drug to Janssen
  3. Akcea and Ionis Announce Acceptance of Marketing Applications in U.S., EU and Canada for Volanesorsen for the Treatment of FCS
  4. Ionis Pharmaceuticals Inc. Sets Itself Up for Growth
  5. Akcea Initiates AKCEA-ANGPTL3-LRx Phase 2 Program in Patients with Rare Hyperlipidemias
  6. New Research: Key Drivers of Growth for Williams-Sonoma, U.S. Silica, RH, Ionis, Burlington, and McCormick & Company – Factors of Influence, Major Initiatives and Sustained Production
  7. Ionis Pharmaceuticals' Earnings Results Fuel Volatility
  8. Edited Transcript of IONS earnings conference call or presentation 7-Nov-17 4:30pm GMT
  9. Ionis Pharmaceuticals, Inc. – Value Analysis (NASDAQ:IONS) : November 9, 2017
  10. Ionis Licenses Novel Antisense Drug for the Treatment of Centronuclear Myopathy to Dynacure
  11. Ionis Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IONS-US : November 8, 2017
  12. Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
  13. Ionis Shares Dip After Third-Quarter Sales, Earnings Miss
  14. Ionis Pharmaceuticals, Inc. to Host Earnings Call
  15. Ionis (IONS) Beats on Q3 Earnings, Revenues Miss
  16. Ionis Pharmaceuticals misses Street 3Q forecasts

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171184136
  2. 8-K - Current report 171181102
  3. 8-K - Current report 171170641
  4. CT ORDER - Confidential treatment order 171150254
  5. 8-K - Current report 171049664
  6. 8-K - Current report 171025738
  7. S-8 - Securities to be offered to employees in employee benefit plans 171015978
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 171015883
  9. 8-K - Current report 171013237
  10. SC 13D - General statement of acquisition of beneficial ownership